


## Venue

Harnack-Haus of the Max-Planck Society  
 Ihnestraße 16-20, 14195 Berlin  
 26.04.23, 12:00 – 19:00  
 27.04.23, 9:00 – 16:15



## Addresses of speakers, chairpersons and moderators

### Charité – Universitätsmedizin Berlin

Dr. Francis Baumgartner  
 Prof. Dr. Lars Bullinger  
 PD Dr. Antonia Busse  
 Prof. Dr. Björn Chapuy  
 Prof. Dr. Frederik Damm  
 PD Dr. Martin Janz  
 Prof. Dr. Ulrich Keller  
 Prof. Dr. Jan Krönke  
 Dr. Corinna Leng  
 Prof. Dr. Stephan Mathas  
 Dr. Rebecca Wurm-Kuczera

### Charité – Universitätsmedizin Berlin Berliner Institut für Gesundheitsforschung in der Charité

Prof. Dr. Il-Kang Na

### Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Berlin

Prof. Dr. Kathrin De la Rosa  
 Dr. Simon Haas  
 PD Dr. Uta Höpken  
 Dr. Philipp Mertins  
 Prof. Dr. Nikolaus Rajewsky

### Hôpital Saint-Louis, France

Prof. Dr. Catherine Thieblemont

### Institute of Oncology Research (IOR), Switzerland

Prof. Dr. Davide Rossi

### Klinikum der Ludwig-Maximilians-Universität München

Prof. Dr. Marion Subklewe  
 Prof. Dr. Oliver Weigert

### Klinikum Stuttgart

Prof. Dr. Gerald Illerhaus

### Medical University of Vienna, Austria

Prof. Dr. Philipp Staber

### Technische Universität München

Prof. Dr. Roland Rad

### Universitätsklinikum Essen

Prof. Dr. Christian Reinhardt

### Universitätsklinikum Freiburg

PD Dr. Florian Scherer

### Universitätsklinikum Halle (Saale)

Prof. Dr. Mascha Binder

### Universitätsklinikum Heidelberg

Prof. Dr. Sascha Dietrich

### Universitätsklinikum Frankfurt a. M.

Prof. Dr. Thomas Oellerich

### Universitätsklinikum Köln

Prof. Dr. Barbara Eichhorst

### Universitätsklinikum Münster

Prof. Dr. Georg Lenz

### Universitätsklinikum Schleswig-Holstein

Prof. Dr. Christiane Pott

### Universitätsklinikum Ulm

Prof. Dr. Reiner Siebert  
 Prof. Dr. Stephan Stilgenbauer

### Kepler Universitätsklinikum Linz, Austria

Prof. Dr. Clemens Schmitt

## Scientific Management

Prof. Dr. med. Ulrich Keller  
 Prof. Dr. med. Björn Chapuy

## Registration

We kindly ask for registration by registration form via email to:

[Jasmin.Radenkovic@charite.de](mailto:Jasmin.Radenkovic@charite.de)

Subject line starting with: „REGISTRATION“

Application to be certified as educational event has been submitted to Ärztekammer Berlin.

## With the kind support of:
















2023 CONFERENCE

# Berlin Conference on Lymphoma (B-CoL)

Cancer dynamics in time and space  
 Berlin, April 26 - 27 2023  
 Harnack-Haus of the Max-Planck Society



## Dear colleagues and friends,

It is with great pleasure that we invite you to the 2023 Berlin Conference on Lymphoma (B-CoL). After a longer SARS-CoV2 pandemic-triggered break, we now reinvigorate this two-day event that brings together key opinion leaders in the clinical management of lymphoma patients and translational lymphoma researchers.

The scientific topic of the 2023 Berlin Conference on Lymphoma is Cancer dynamics in time and space. The B-CoL will take place at the Harnack-Haus of the Max-Planck Society on April 26 and April 27. Notably, we are pleased to announce Prof. Nikolaus Rajewsky as keynote speaker. We are looking forward to meeting you for this certainly vibrant and stimulating meeting.

Ulrich Keller und Björn Chapuy

# PROGRAM

## Day 1 (April 26 from 12:00 - 19:00)

**12:00** Registration/Welcome reception

**12:45** **U. Keller** – Welcome

### **13:00** Clinic Session I – CLL

*Moderators: L. Bullinger/F. Damm*

- B. Eichhorst** – Treatment algorithms of CLL - quo vadis?
- D. Rossi** – MRD triggered therapy in CLL
- S. Stilgenbauer** – High-risk CLL and Richter - lessons from genomics

**14:30** 1<sup>st</sup> Coffee break

### **15:00** Clinic Session II – Aggressive lymphoma

*Moderators: B. Chapuy/A. Busse*

- G. Lenz** – Treatment algorithm of DLBCL
- C. Thieblemont** – Novel developments for r/rDLBCL
- F. Scherer** – Liquid biopsy guided therapy – are we there?
- R. Wurm-Kuczera** – Patient-reported outcome analysis (short talk)
- G. Illerhaus** – Treatment paradigms for CNS lymphoma/CNS prophylaxis

**17:00** 2<sup>nd</sup> Coffee break

### **17:30** Clinic Session III – Indolent lymphoma

*Moderators: M. Janz/C. Leng*

- C. Pott** – Therapy algorithm MCL and the role of MRD-triggered therapy
- M. Subklewe** – To CART or BITE relapsed/refractory indolent/aggressive lymphoma?
- O. Weigert** – Risk prediction and patient stratification in follicular lymphoma

**18:55** **B. Chapuy** – Closing remarks Day 1

## Day 2 (April 27 from 9:00 - 16:15)

**9:00** **U. Keller** – Welcome

### **9:05** Translational Session I

*Moderators: U. Keller/P. Mertins*

- R. Rad** – Exploiting new targets using functional genomics
- F. Baumgartner** – Single cell sequencing for genome-wide cancer gene discovery screening (short talk)
- B. Chapuy** – Genomic signatures in DLBCL/precision medicine - where are we?

**10:00** 1<sup>st</sup> Coffee break

### **10:20** Translational Session II

*Moderators: U. Keller/P. Mertins*

- M. Binder** – Germline variants in lymphoid malignancies
- R. Siebert** – Epigenetic signatures
- T. Oellerich** – Proteogenomic strategies on lymphoma

### **11:15** Keynote Lecture – Prof. Dr. Nikolaus Rajewsky

**12:00** Lunch break

### **13:00** Translational Session III – Lymphoma as an organ,

*Role of the TME: Moderators: B. Chapuy/S. Mathas*

- K. De la Rosa** – B cells at the crossroad of diversification and malignant transformation
- C. Reinhardt** – Lessons from mouse models
- S. Dietrich** – Intratumoral heterogeneity/CODEX
- S. Haas** – Dissecting tumor heterogeneity and reverse translation

**14:30** 2<sup>nd</sup> Coffee break

### **15:00** Translational Session IV – Development of new

*treatments: Moderators: I-K. Na/J. Krönke*

- C. Schmitt** – Harnessing senescence as a therapeutic target in lymphoma
- U. Höpken** – Novel cellular therapies
- A. Busse** – Adoptive T cell therapies: phase I Charité studies (short talk)
- P. Staber** – Can we EXALT response by ex vivo drug testing?

**16:00** **B. Chapuy** – Closing remarks / Farewell